CSPC in talks for potential licensing deals worth US$5bn

CSPC Pharmaceutical Group (HKEX:1093) announced that it is in negotiations with independent third parties regarding three potential licensing and collaboration transactions related to the development, manufacturing, and commercialization of certain pharmaceutical products, including epidermal growth factor receptor antibody drug conjugate (EGFR-ADC). The potential upfront, development milestone, and commercialization milestone payments could total approximately US$5 billion. One of the transactions is at an advanced stage and is expected to be finalized in June 2025. The company cautioned that terms and conditions are yet to be finalized, and no definitive agreement has been reached, so the transactions may or may not proceed.